Oculis Holding AG filed a report of foreign issuer on November 3, 2026, disclosing its unaudited financial results for the three and nine months ended September 30, 2026, and announcing the renewal of its at-the-market offering program for up to $125 million in ordinary shares.

Key Highlights

  • ATM Program renewed: Oculis entered into Amendment No. 1 to its Amended and Restated Sales Agreement with Leerink Partners, LLC on November 3, 2026.
  • Offering capacity: The Amended Sales Agreement allows Oculis to offer and sell ordinary shares with an aggregate offering price of up to $125 million.
  • Registration basis: Any issuance under the Amended Sales Agreement will be made pursuant to the company's Form F-3 registration statement filed with the SEC on March 4, 2026 (File No. 333-294011).
  • Quarterly results attached: Unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2026 were filed as Exhibit 99.1.
  • Swiss legal opinion included: An opinion from VISCHER AG, the company's Swiss counsel, relating to the underlying shares was filed as Exhibit 5.1.
  • Signed by CFO: The report was signed by Sylvia Cheung, Chief Financial Officer of Oculis Holding AG.

Oculis Extends At-the-Market Share Offering Facility with Leerink Partners

According to the filing, Oculis Holding AG, a Swiss holding company incorporated in Zug, Switzerland and listed on NASDAQ:OCS, entered into Amendment No. 1 to its Amended and Restated Sales Agreement with Leerink Partners, LLC on November 3, 2026. The amendment renews the company's existing at-the-market offering program, under which Oculis may offer and sell ordinary shares at its sole discretion, up to an aggregate offering price of $125 million. The company disclosed that sales under the program, if any, would be conducted pursuant to its effective registration statement on Form F-3 (File No. 333-294011), which was originally filed with the Securities and Exchange Commission on March 4, 2026.

The filing noted that the description of the Amended Sales Agreement is "not complete and is qualified in its entirety by reference to the full text of the Amended Sales Agreement," a copy of which was filed as Exhibit 1.1. The filing also incorporated certain exhibits, including Exhibits 1.1, 5.1, 23.1, 99.1, and 99.2, by reference into multiple existing registration statements on Form S-8 (File Nos. 333-271938, 333-287806, and 333-298073) and Form F-3 (File Nos. 333-271063, 333-278409, 333-291426, and 333-294011). Exhibit 99.3, the press release dated November 3, 2026, was explicitly excluded from that incorporation by reference.

Alongside the ATM renewal, the filing attached unaudited condensed consolidated interim financial statements and a Management's Discussion and Analysis of Financial Condition and Results of Operations covering the three and nine months ended September 30, 2026, filed as Exhibits 99.1 and 99.2 respectively. The filing expressly stated it "shall not constitute an offer to sell or the solicitation of an offer to buy" the securities discussed.

What Was Disclosed

Oculis Holding AG reported its unaudited results for the period ended September 30, 2026, and disclosed an amendment renewing its at-the-market offering program, permitting ordinary share sales of up to $125 million through Leerink Partners, LLC, under an existing Form F-3 registration statement.